An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With nAMD

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions

To Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD

Interventions

DRUG

LX109

LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye

All Listed Sponsors

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT06022744 - An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With nAMD | Biotech Hunter | Biotech Hunter